# Evaluation of the ReX-C System, in Patients Receiving CFTR Modulators for the Treatment of Cystic Fibrosis (CF).

> **NCT04215796** · NA · UNKNOWN · sponsor: **Dosentrx Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Cystic Fibrosis
- Adherence, Medication

## Interventions

- **DEVICE:** ReX-C system

## Key facts

- **NCT ID:** NCT04215796
- **Lead sponsor:** Dosentrx Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-12
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-07-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04215796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04215796, "Evaluation of the ReX-C System, in Patients Receiving CFTR Modulators for the Treatment of Cystic Fibrosis (CF).". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04215796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*